General discussion, page-14965

Hi Flectional, I know the other company you're referring to (as I'm also a shareholder), I am curious btw, but presumably your position in the other is higher than IHL on a risk-adjusted basis given the nature of biotech?

More importantly, for everyone who are existing shareholders (and forgive me as I've literally just come across IHL / researching it this very week and it's christmas!), what are your thoughts regarding competitive landscape, not so much with existing standard of care CPAP (given the low adherence argument is well understood by all), but specifically in relation to other drug companies? Not sure who has done work in earlier threads (in which case please point me there!), but take the likes of Apnimed as an example, whom recently released quite decent phase 2B trial results for their AD109 product candidate (see link below) and are liaising with FDA to potentially proceed with phase 3 come 2023, aren't there other players out there that are ahead of IHL commercialisation wise? I understand that this company is not betting the farm on purely 42X, but presumably even if one buys into the M&A potential as the re-rate thesis, would have thought 49X would be the most valuable from a sum-of-the-parts perspective no? (merely assuming that product candidates with largest TAM and are furthest down the clinical trial pathway would be most valuable to the big pharma's).

Link: https://apnimed.com/apnimed-announces-positive-topline-results-for-mariposa-trial-of-ad109/

Anyways thanks for any answers in advance so I can continue to do my own research, otherwise enjoy the year end festivities!